小细胞肺癌分子分型:向临床实践转化的挑战

Molecular Subtype of Small Cell Lung Cancer:Challenge for Transforming into Clinical Practice

小细胞肺癌(small cell lung cancer,SCLC)是肺癌的组织学亚型之一,特点是高增殖、早转移、易耐药和复发。数年来SCLC一直被视为一种同质性疾病,治疗采用统一的放化疗策略。尽管早期疗效显著,但耐药和复发很快出现,缺乏满意的治疗效果,这可能是因为目前对SCLC的肿瘤异质性认识不足所导致。最近,临床前研究提出了基于谱系转录因子相对高表达定义的SCLC分子分型概念。本文主要阐述SCLC分子分型的现状和相关最新发现,强调分子分型转化在临床实践中所遇到的问题,旨在增进对SCLC分子分型研究进展的认识。

Small cell lung cancer(SCLC),one of the histological subtypes of lung cancer,is characterized by high proliferation,early metastasis,susceptibility to drug resistance and recurrence.For several years,SCLC has always been regarded as a homogeneous disease,treated with a unified radiotherapy and chemotherapy strategy.Despite significant early therapeutic effects,drug resistance and recurrence occur quickly,and there is a lack of satisfactory treatment results,which may be due to insufficient understanding of the tumor heterogeneity of SCLC at present.Recently,the concept of SCLC molecular subtype based on the definition of relatively high expression of lineage transcription factors has been proposed in preclinical studies.This article mainly elaborates on the current status and latest findings of SCLC molecular subtype,emphasizing the potential problems that molecular typing may encounter in clinical practice,aiming to promote understanding of the research progress of molecular subtype in SCLC.